Reading time: 9 minutes
Dermatology is not a field most patients cross borders for — most common skin conditions are handled at home. But in a narrow set of scenarios, travelling to China does carry value: the cost of biologics for psoriasis and atopic dermatitis, where domestic biosimilars are materially cheaper than originator products at home; the established Chinese pathway for vitiligo combining phototherapy with topicals and increasingly newer agents; the mature hair restoration market (microneedling, PRP, FUE transplantation); and second-opinion evaluation of difficult skin tumours. This article works through these areas by condition, with realistic indications and typical costs.
1. Psoriasis — Access to Biologics Is the Core Value
Modern psoriasis treatment has been transformed by biologics. The main classes available in China:
| Class | Representative agents | Available in China |
|---|---|---|
| Anti-TNF | Adalimumab, etanercept, infliximab | Yes |
| IL-17 inhibitors | Secukinumab, ixekizumab, bimekizumab | Yes |
| IL-23 inhibitors | Guselkumab, risankizumab, tildrakizumab | Yes |
| IL-12/23 | Ustekinumab | Yes |
| JAK inhibitors | Upadacitinib, tofacitinib, topical agents | Yes |
| PDE-4 inhibitor | Apremilast | Yes |
Indicative cost advantage:
- Adalimumab plus domestic biosimilars: annual treatment cost roughly USD 5,000–9,000 in China, against substantially higher originator pricing at home
- Several domestic IL-17 and IL-23 agents are entering the market and continuing to lower cost over time
2. Atopic Dermatitis (Eczema)
- Dupilumab (Dupixent): approved in China
- JAK inhibitors: upadacitinib, abrocitinib (oral); topical agents including ruxolitinib cream available in some markets
- Topical therapy: tacrolimus, pimecrolimus, and topical PDE-4 agents in selected formulations
3. Vitiligo
China has a large vitiligo patient population and a well-developed specialty network.
Mainstream treatments:
- NB-UVB narrow-band phototherapy (home units and hospital booths)
- 308 nm excimer laser
- Topical therapy: tacrolimus, calcipotriol, corticosteroids
- JAK inhibitor topical: ruxolitinib cream (Opzelura), with access varying by region
- Melanocyte transplant / epidermal grafting: offered at selected leading centres
4. Hair Loss (Androgenetic, Alopecia Areata, Female Pattern)
- Minoxidil plus finasteride: standard
- JAK inhibitors: baricitinib for alopecia areata, approved in China
- PRP injection: autologous platelet-rich plasma
- Hair transplant: FUE / FUT techniques are well established; large Chinese hair-restoration chains (Yonghe, Xinsheng, Bosley-China, DaMai) operate at scale
- FUE pricing in China: typically RMB 10–30 per follicular unit, equating to roughly USD 1.5–4.5 per unit at standard chains, with premium techniques higher. A typical 2,500-unit transplant lands around USD 4,000–10,000 in China against US pricing of roughly USD 6–12 per unit
5. Skin Tumours
Benign lesions / naevi / seborrhoeic keratoses: generally more economical to handle at home Basal cell carcinoma / squamous cell carcinoma: standard excision, with Mohs surgery at selected leading centres Melanoma: multidisciplinary evaluation; the cross-border value lies in full genomic profiling and access to systemic therapy. Several PD-1 agents developed in China (toripalimab, tislelizumab, sintilimab, camrelizumab) carry pricing materially below imported originators
6. Hospitals to Consider
| Hospital | City |
|---|---|
| Hospital for Skin Diseases, Chinese Academy of Medical Sciences (Nanjing Institute of Dermatology) | Nanjing |
| Peking Union Medical College Hospital, Dermatology | Beijing |
| Huashan Hospital of Fudan University, Dermatology | Shanghai |
| Peking University First Hospital, Dermatology and Venereology | Beijing |
| First Affiliated Hospital of China Medical University, Dermatology | Shenyang |
| West China Hospital, Dermatology | Chengdu |
| Peking University People’s Hospital, Dermatology | Beijing |
| Shanghai Skin Disease Hospital | Shanghai |
7. Typical Process
Biologic initiation for psoriasis or atopic dermatitis (3–5 days):
- Day 1: dermatology evaluation and labs
- Day 2: tuberculosis and hepatitis B screening if indicated
- Days 3–5: initiation injection and observation
Vitiligo comprehensive assessment and phototherapy initiation (3–5 days):
- Days 1–2: evaluation
- Days 3–5: phototherapy initiation and topical regimen
8. Typical Costs (USD, 1 USD = 6.5 RMB)
| Item | Public tertiary | High-end private |
|---|---|---|
| Dermatology specialist consultation | 50–150 | 100–300 |
| Comprehensive dermoscopy evaluation | 100–300 | 200–500 |
| Psoriasis biologic monthly cost | See Article #65 | Same |
| Dupilumab (eczema) monthly | 350–700 | 500–1,000 |
| 308 nm excimer laser (per session) | 80–200 | 150–400 |
| FUE hair transplant (per follicular unit) | USD 1.5–4.5 | USD 3–7 |
| Typical 2,500-unit FUE total | 4,000–10,000 | 8,000–17,000 |
9. Handing Care Back Home
- Biologics can be continued at home, with the caveat that brand and biosimilar identity may differ across countries
- Phototherapy can be continued at home (a home NB-UVB unit is available in many markets)
- JAK inhibitors and topical agents are generally accessible at home
10. What MedCareInChina Can and Cannot Do on the Dermatology Pathway
Our two products are Remote Consultation and In-China Accompanied Care.
- Remote Consultation: a USD 800 single-expert consultation with a dermatologist who reviews your photographs and records
- In-China Accompanied Care: hospital accompaniment with translation through evaluation, treatment initiation, and procedures such as hair transplant
What we do not do: long-term dermatology management, post-transplant maintenance at home.
11. Action Checklist
- Bring clear photographs of skin lesions (multiple angles, with scale) and a medication history
- Engage a remote consultation to assess plan
- Apply for an S2 visa
- Plan 3–10 days in China depending on the procedure
- Continue maintenance therapy at home after returning
Sources
[1] Chinese Society of Dermatology — Treatment guidelines for psoriasis and atopic dermatitis: https://www.csd.org.cn/ [2] National Medical Products Administration of China — Approval records for dupilumab, upadacitinib, baricitinib and similar agents: https://www.nmpa.gov.cn/ [3] American Academy of Dermatology — Treatment Guidelines: https://www.aad.org/ [4] European Academy of Dermatology and Venereology (EADV) — Practice guidelines
